Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To assess the value of <sup>18</sup>F-FDG PET and MR-IVIM parameters before and during concurrent chemoradiotherapy (CCRT) for evaluating early treatment response and predicting tumor recurrence in patients with locally advanced cervical cancer (LACC) using a hybrid PET/MR scanner.
|
31493211 |
2020 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To determine the diagnostic utility of posttreatment surveillance whole-body <sup>18</sup>F-FDG PET/CT in detecting local tumor recurrence (R), regional lymph-node metastasis (LM), and distant metastasis (DM) in asymptomatic sinonasal cancer patients.
|
30604061 |
2019 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MRI and <sup>18</sup> F-FDG PET/MRI datasets were analyzed in separate sessions by two readers for tumor recurrence or metastases.
|
30548894 |
2019 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A high uptake of FDG was correlated with a more proliferative biological behavior and is a risk factor for tumor recurrence.
|
31802943 |
2019 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study was to evaluate the prognostic value of metabolic parameters on F-18-FDG PET/CT and the status of human papillomavirus (HPV) infection and known prognostic variables for predicting tumor recurrence and investigating a prognostic model in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT).
|
31234933 |
2019 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Extraordinarily high F-FDG uptake was seen in right ramus (SUVmax, 17.4), left body mandible (SUVmax, 13.6) with left pleural deposits (SUVmax, 17.4).Tumor recurrence was suspected.
|
30789393 |
2019 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The FDG PET/CT brain scan showed increased tracer uptake at the margin of the previous resected tumor, suggesting the possibility of tumor recurrence.
|
30300207 |
2018 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer.
|
30532215 |
2018 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Preoperative F-18-fluoro-2-deoxy-glucose positron emission tomography (18F-FDG PET) imaging results appear to predict tumor recurrence and patient survival.
|
29629352 |
2018 |
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To evaluate the prognostic value for predicting tumor recurrence of intratumoral metabolic heterogeneity and traditional quantitative metabolic parameters on pre-treatment F-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT).
|
29163839 |
2017 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The purpose of our case report is to emphasize the role of FDG PET/CT in the assessment of tumor recurrence and extracranial bone metastases from anaplastic astrocytoma.
|
28591062 |
2017 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Comparison between MR Perfusion and 18F-FDG PET in Differentiating Tumor Recurrence from Nonneoplastic Contrast-enhancing Tissue
|
28441783 |
2017 |
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A pilot study for texture analysis of <sup>18</sup>F-FDG and <sup>18</sup>F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery.
|
28770274 |
2017 |